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on behalf of the Acute Myocardial Infarction Study Group
Zwolle, the NetherlandsObjectives The aim was to investigate whether a strategy of direct drug-eluting stent (DES)
implantation without pre-dilation is associated with a reduced incidence of restenosis compared with
CS with pre-dilation or provisional stenting (PS).
Background Previous studies were performed comparing direct stenting (DS) with conventional
stenting (CS) after pre-dilation; however, none of these in the DES era. Therefore, the STRESSED (direct
Stenting To reduce REStenosis in Stent Era with Drug elution) study was designed and carried out.
Methods A total of 600 patients with angina pectoris or recent myocardial infarction were
randomized to a DS, CS, or PS strategy. The primary endpoint was the mean minimal lumen diameter
at 9-month follow-up angiography. Secondary endpoints were clinical procedural success deﬁned as
angiographic success without in-hospital major adverse cardiac events (MACE), and MACE at 9-month
and 2-year follow-up.
Results Stent implantation in the DS group was 98%, 99% in the CS group, and 77% in the PS group.
Percutaneous coronary intervention success was 99% in all groups. The minimal lumen diameter at
9-month follow-up was 2.12  0.58 mm (DS), 2.17  0.67 mm (CS), and 1.99  0.69 mm (PS), p ¼ 0.556
for comparison of DS with CS, p ¼ 0.073 for comparison of DS with PS. The absolute difference
was 0.05 (DS to CS), 95% conﬁdence interval: 0.19 to 0.09, p ¼ 0.48 and 0.13 (DS to PS),
conﬁdence interval: 0.02 to 0.27, p ¼ 0.087. Restenosis was found in 3.4% (DS), 6.7% (CS), and
11.5% (PS), p ¼ 0.025. At 9-month and 2-year follow-up, MACE occurred in 6.8% and 11.5% (DS), 4.6%
and 10.3% (CS), and 7.6% and 13.8% (PS) (p ¼ 0.439 and 0.536), respectively.
Conclusions Direct DES implantation compared with conventional DES implantation did not reduce
restenosis. Provisional stenting, however, was associated with a higher rate of restenosis. This did not
translate into a difference in the rate of MACE. (STRESSED study: direct Stenting To reduce REStenosis
in Stent Era with Drug elution; ISRCTN41213536) (J Am Coll Cardiol Intv 2014;7:751–8) ª 2014 by the
American College of Cardiology FoundationFrom the Isala Klinieken, Zwolle, the Netherlands. The study was partly funded by an unrestricted grant from Medtronic.
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752Direct stenting (DS), without pre-dilation, has been shown
to be a safe and effective treatment modality in elective pa-
tients as well as in patients who undergo percutaneous cor-
onary intervention (PCI) because of unstable angina. Success
rates vary from 90% to 98% (1–8). DS may reduce procedure
length, the use of contrast agent, and the number of balloons
and wires needed, resulting in a reduction of procedure-
related costs (9). It also has some potential disadvantages that
might increase procedural risks and may lead to suboptimalSee page 759clinical results. A higher risk of failure to initially cross
the lesion, errors in stent placement, incorrect stent sizing,Abbreviations
and Acronyms
ACC/AHA = American
College of Cardiology/
American Heart Association
BMS = bare-metal stent(s)
CABG = coronary artery
bypass grafting
CS = conventional stenting
cTnT = cardiac troponin T
DES = drug-eluting stent(s)
DS = direct stenting
MACE = major adverse
cardiac event(s)
MLD = minimal lumen
diameter
PCI = percutaneous coronary
intervention
PS = provisional stenting
TIMI = Thrombolysis In
Myocardial Infarctionunderexpansion, stent dislodg-
ment, and embolization are pos-
sibilities. Furthermore, calciﬁed,
tortuous, or angulated lesions and
chronic total occlusions are often
not suitable for a DS approach and
formed a reason for exclusion in
all previous stent- trials comparing
DS and conventional stenting
(CS) strategies.
The potential advantage of
DS in reducing the risk of in-
stent-restenosis was suggested in
an experimental study by Rogers
et al. (10), who showed that un-
damaged remnant endothelial cells
that remain between the stent
struts regenerate, and therefore
may reduce the degree of intimal
hyperplasia compared with pre-
vious balloon dilation.
Furthermore, pre-dilation may
induce dissection necessitating
longer stents compared with DS without pre-dilation, and this
may increase restenosis (11). On the other hand, after pre-dila-
tion, a wider diameter stent may be chosen, resulting in a larger
minimal luminal diameter (MLD) after intervention, which it-
self is associated with a lower rate of restenosis (12).
DES have been successful in reducing restenosis after
percutaneous coronary intervention (PCI) by 50% to 90%
(13,14).When aDES is placed after pre-dilation, it is of critical
importance to cover the whole dilated area with the stent. This
problem is not present with DS. Therefore, the concept of
DS might be beneﬁcial in patients receiving a DES. There
are no randomized trials comparing DS with a conventional
approach in the second-generation DES era, and no previous
studies comparingDSwithCShad a provisional arm included.
The aim of this study was to investigate whether a strategy of
DS without pre-dilation is associated with a reduced incidenceof restenosis at 9-month follow-up angiography comparedwith
CS with pre-dilation or a strategy of provisional stenting (PS).
Methods
Study population. Eligible were men and women younger
than 85 years of age with stable or unstable angina pectoris or a
recent (<30 days) myocardial infarction with objective
evidence of myocardial ischemia. Lesions were single Amer-
ican College of Cardiology/American Heart Association
(ACC/AHA) Task Force classiﬁcation type A, B1, or B2
noncalciﬁed target lesions with >50% and <100% diameter
stenosis according to the visual estimation of the investigator.
Exclusion criteria were acute ST-segment elevation
myocardial infarction, unstable angina pectoris classiﬁed as
Braunwald category IIIB or C, bifurcation lesions with a side
branch >2.0 mm in diameter, left main coronary artery
lesions, ostial lesions, left ventricular ejection fraction <30%,
contraindications to inhibit platelet function with aspirin
and clopidogrel, and contraindications to follow-up angiog-
raphy (severe peripheral vessel disease or creatinine-clearance
<30 ml/min).
Randomization. Randomization to DES implantation with-
out (DS group) and with (CS group) balloon pre-dilation
or PS (PS group) was assigned by a sealed envelope, located
in the catheterization laboratory.
Procedural protocol. In the CS group, coronary angioplasty
was performed using standard techniques, with a balloon
size chosen according to the angiographic arterial diameter.
One or more inﬂations were performed to obtain a visually
estimated residual vessel stenosis of <30%, after which the
stent was implanted. Identical techniques were used in the
DS group except for pre-dilation. Crossover to balloon pre-
dilation was allowed when the stent could not be successfully
advanced through the lesion. PS was allowed only if visual
diameter stenosis after repeated balloon dilation was >30%,
if there was a dissection grade D1 or higher occurred, or if
there was decreased Thrombolysis In Myocardial Infarction
(TIMI) ﬂow after repeated dilation.
In all groups, an inﬂation pressure of at least 10 atm was
recommended. DES were used in all patients. During this
study, we used 2 second-generation DES; the zotarolimus-
(Endeavour, Medtronic, Minneapolis, Minnesota) and the
everolimus- (PROMUS, Boston Scientiﬁc, Natick, Massa-
chusetts) coated stents. Stent dimension and length were
chosen according to lesion length.
All patients received aspirin 160 mg/day and clopidogrel
300mgbolus (preferably>12hbefore angioplasty) and75mg/
day for at least 6 months with the exception for patients who
did not receive a stent but received 1-month treatment with
clopidogrel. A single intravenous bolus of 5,000 U of heparin
was given at the beginning of the procedure in all patients.
All patients signed informed consent. This trial was
conducted in accordance with the Helsinki Declaration and
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753approved by the Medical Ethics Committee of the Isala
Clinics, Zwolle, the Netherlands.
Deﬁnitions. Procedure time was deﬁned as the interval
between placement of the arterial sheath and removal of the
guiding catheter. Immediate angiographic success was de-
ﬁned as angioplasty with or without stenting with a reduction
in stenosis <50% by quantitative coronary analysis, in the
absence of dissection higher than grade D1 according to the
National Heart, Lung, and Blood Institute criteria (15) and a
TIMI ﬂow grade 3. Clinical procedural success was deﬁned
as immediate angiographic success without major in-hospital
complication, including death, myocardial infarction, stent
thrombosis, or emergency coronary artery bypass grafting
(CABG). Myocardial infarction was deﬁned by the presence
of new Q waves or creatine kinase level or myocardial band
fraction at least twice the upper limit of normal. Lesions were
classiﬁed according to the deﬁnitions recommended by the
ACC/AHA Task Force.
Endpoints. The primary endpoint was the mean MLD at
follow-up angiography. Secondary endpoints were deﬁned
as clinical procedural success and rate ofMACEat 9- and 2-year
follow-up. Exploratory endpoints were the amount of post-
procedural cardiac troponin T (cTnT) release and angiographic
restenosis (>50%) at 9-month follow-up angiography.
Qualitative and quantitative coronary analysis. Coronary
angiograms were obtained before and immediately after an-
gioplasty and at 9-month follow-up. Standard acquisition
procedures were followed for qualitative and quantitative
coronary angiography analysis. To improve the accuracy and
reproducibility of measurements, intracoronary isosorbide
dinitrate (1 to 3mg) was given before the initial and ﬁnal post-
stent placement angiograms. Angiograms were recorded on a
CD-ROM. Matched orthogonal views were used for quan-
titative analysis at each control. Dye-ﬁlled guiding catheters
were used for magniﬁcation calibration. Data collection
included assessment of TIMI ﬂow grade, lesion eccentricity,
estimation of thrombus load, and ACC/AHA classiﬁcation.
An independent laboratory (DIAGRAM, Zwolle, the
Netherlands) performed routine quantitative coronary angi-
ography measurements using the Coronary Angiography
Analysis II System. Two orthogonal angiographic views with
minimized vessel foreshortening were obtained, and the
angiogram showing the most severe stenosis was selected for
quantitative coronary analysis. Post-procedure and follow-up
angiograms, which duplicate the initial orthogonal views,
were obtained after the removal of the balloon and guidewire.
Follow-up. Coronary angiography was required at 9 months
in all patients with angiographic procedural success and no
target lesion revascularization during hospital stay and fol-
low-up. Coronary angiography could be prematurely per-
formed on the basis of clinical indications; it was used as the
follow-up angiogram in the case of restenosis or if performed
after 4 months. When it was performed within 4 months
without evidence of restenosis, angiographic control wasrepeated at 9months. All major clinical events including death,
myocardial infarction, readmission to hospital for unstable
angina pectoris, and the need for additional revascularization of
the target vessel were monitored at the time of repeated angi-
ography or by phone at 9 months and 2 years for all patients.
Statistical analysis. The study was designed to demonstrate
the superiority of DS based on the assumption that at
follow-up angiography, the mean MLD in the DS group
was at least 0.15 mm larger than the mean MLD in the CS
group or that the mean MLD in the DS group is at least
0.15 mm larger than the mean MLD in the PS group (based
on the preceding DIRECT-2 study [Direct Stenting
Strategy vs Conventional or Provisional Stenting]).
Previous studies have shown that it is reasonable to as-
sume that the MLD measurement follows a normal distri-
bution. A group mean of w2.2 mm with an SD of w0.4
mm was expected, allowing for a type I error of 2.5%. A
sample of 159 patients per group will give 90% power to
prove superiority of DS compared with a strategy of pre-
dilation stenting or PS stenting. To compensate crossover
and losses for angiographic follow-up, the sample was
enlarged by 25% to 600 patients. The data were evaluated by
intention-to-treat analysis. Because of crossover, data were
also analyzed under per-protocol approach.
For comparisons between groups, the chi-square test (or,
in case of <5 expected observations, the Fisher exact test)
was used. For comparisons of continuous variables, analysis
of variance was used according to the type of data and their
distribution. Statistical signiﬁcance was considered by a
2-tailed p value <0.05. Relative risks were calculated with
95% conﬁdence intervals. MACE survival Kaplan-Meier
curves were obtained and compared by means of the log-rank
test. In the pairwise comparisons, we adjusted for multiple
testing by dividing the alpha by 2.
A 2-sided p value <0.025 was considered to be statisti-
cally signiﬁcant in the pairwise test.
Results
Baseline characteristics. We enrolled 600 patients in this
trial between 2005 and 2010 (Fig. 1). Patients were equally
randomized into 3 groups; DS (n ¼ 198), CS (n ¼ 201),
and PS (n ¼ 201). All 3 arms were well matched with
respect to demographic and angiographic characteristics at
baseline (Table 1). In the DS group, 18% of the lesions
required pre-dilation because of the inability of the stent to
cross the lesion. In the PS group, a stent was implanted in
77% of the patients. No differences were observed in pro-
cedural time between DS and pre-dilation. PCI was suc-
cessful in 99%, without differences between the groups. Five
patients (0.8%) experienced in-hospital myocardial infarc-
tion (2 in the CS group and 3 in PS group) due to side
branch occlusion and in 1 case due to dissection distal to the
stent, requiring repeat PCI of the target vessel.
Figure 1. Flowchart Showing Follow-up
angio ¼ angiography; BMS ¼ bare metal stent; CABG ¼ coronary artery bypass grafting; EF ¼ ejection fraction; IC ¼ informed consent; LM ¼ left main coronary artery;
PCI ¼ percutaneous coronary intervention; QCA ¼ quantitative coronary analysis.
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754Before leaving the hospital, 6 patients (1.0%) under-
went CABG after an initial unsuccessful PCI. There
were no in-hospital deaths and no signiﬁcant differences
in in-hospital events among the 3 groups (Table 2).
The biochemical exploratory endpoint of cTnT release
post-PCI (>0.05 ng/ml) occurred signiﬁcantly more in the
CS group: DS, 11.2%; CS, 24.8%; PS 21.9%; p ¼ 0.008 for
comparison of DS with CS, p ¼ 0.031 for comparison of
DS with PS, and p ¼ 0.625 for comparison of CS with PS.
Angiographic outcome. Follow-up angiography was per-
formed at 9 months in 72.9% of the patients. Follow-up was
missing because of patient refusal (21%), death (1%), or
angiograms did not meet the qualitative criteria for accurate
analysis (3%). At baseline, patients who declined follow-up
angiography were older (65.3  10.2 years vs. 63.1  9.5
years, p ¼ 0.007) and more often female (34.3 vs. 23.0%,
p ¼ 0.004). There were no differences in clinical and
angiographic characteristics.
The primary endpoint, MLD at 9 months, was not
signiﬁcantly different when comparing DS with CS and
PS (DS, 2.12  0.58; CS, 2.17  0.67; PS, 1.99  0.69;p ¼ 0.556 for comparison of DS with CS and p ¼ 0.073 for
comparison of DS with PS).
The absolute difference was 0.05 (DS to CS), 95%
conﬁdence interval: 0.19 to 0.09; p ¼ 0.480 and 0.13 (DS
to PS), 95% conﬁdence interval: 0.02 to 0.27; p ¼ 0.087.
The presented results are for the intention-to-treat popu-
lation. Analysis under a per-protocol approach showed similar
results: for the primary endpoint,DS, 2.15 0.54;CS, 2.20
0.64; PS, 2.07  0.62; p ¼ 0.651 for comparison of DS with
CS and p ¼ 0.145 for comparison of DS with PS.
Immediately after angioplasty, there was signiﬁcantly larger
diameter stenosis in the PS group (DS, 8.29  10.62%; CS,
7.84 10.06%; PS, 12.08 13.37; p¼ 0.783 for comparison
of DS with CS, p ¼ 0.013 for comparison of DS with PS).
Late lumen loss in the PS group exceeded that in the
DS group and the CS group (PS, 0.36  0.49 mm vs.
0.24  0.47 mm [CS] vs. 0.29  0.55 mm [DS]; p ¼ 0.526
for comparison of DS with CS and p ¼ 0.017 for com-
parison of DS with PS) (Table 3). Figure 2 presents the
cumulative distributions of acute gain, late loss, and net gain
for the 3 treatment strategies.
Table 1. Baseline Characteristics
Direct
Stenting
Conventional
Stenting
Provisional
Stenting p Value
Age, yrs 63.9  9.3
(n ¼ 198)
63.1  9.9
(n ¼ 201)
64.6  10.1
(n ¼ 201)
0.169
Male 151/198 (76.3) 150/201 (74.6) 141/201 (70.1) 0.356
BMI 27.5  3.9 27.9  4.2 27.3  3.9 0.542
Hypertension 93/198 (47.0) 106/201 (52.7) 110/201 (54.7) 0.274
Diabetes mellitus 40/198 (20.2) 43/201 (21.4) 40/201 (19.9) 0.926
Smoking 34/198 (17.2) 41/200 (20.5) 38/201 (18.9) 0.698
Hyperlipidemia 167/198 (84.3) 162/201 (80.6) 156/201 (77.6) 0.231
Previous MI 47/198 (23.7) 29/201 (14.4) 38/201 (18.9) 0.060
Previous PCI 47/198 (23.7) 30/201 (14.9) 44/201 (21.9) 0.068
Previous CABG 5 (198) (2.5) 12/201 (6.0) 11/201 (5.5) 0.212
Target lesion vessel
LAD 83/196 (42.3) 89/201 (44.3) 80/200 (40.0) 0.686
LCX 60/196 (30.6) 48/201 (23.9) 46/200 (23.0) 0.167
RCA 53/196 (27.0) 63/201 (31.3) 74/200 (37.0) 0.102
Lesion length, mm 10.80  5.37 10.89  5.01 10.84  6.47 0.523
Calciﬁcation 0.061
Little or none 148/196 (75.5) 169/203 (83.3) 167/199 (83.9)
Moderate or heavy 48/196 (24.5) 34/203 (16.7) 32/199 (16.1)
Angulation 0.935
None 191/196 (97.4) 198/203 (97.5) 193/199 (97.0)
Moderate 5/196 (2.6) 5/203 (2.5) 6/199 (3.0)
Modiﬁed ACC/AHA
lesion type
0.204
A 88/197 (44.7) 101/203 (49.8) 113/199 (56.8)
B1 90/197 (45.7) 83/203 (40.9) 70/199 (35.2)
B2 19/197 (9.6) 19/203 (9.4) 16/199 (8.0)
Bifurcation lesion 0.515
No major branch 165/196 (84.2) 172/203 (84.7) 175/199 (87.9)
Ostial lesion 3/196 (1.5) 6/203 (3.0) 2/199 (1.0) 0.379
Values mean  SD or n/N (%).
ACC/AHA ¼ American College of Cardiology/American Heart Association; BMI ¼ body mass
index; CABG ¼ coronary artery bypass graft surgery; LAD ¼ left anterior descending artery;
LCX ¼ left circumﬂex artery; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary inter-
vention; RCA ¼ right coronary artery.
Table 2. Clinical Events
In-Hospital Events
Direct
Stenting
Conventional
Stenting
Provisional
Stenting p Value
Death 0 0 0
MI 0/198 2/201 (1.0) 3/201 (1.5) 0.380
Repeat PCI 0/198 1/201 (0.5) 0 1.000
CABG 3/198 (1.5) 1/201 (0.5) 2/201 (1.0) 0.542
Clinical procedural
success
192/197 (96.9) 195/200 (97.5) 193/201 (96.0) 0.614
9-Month follow-up
Control
angiography
145/190 (76.3) 142/195 (72.8) 135/194 (69.6) 0.334
MACE 13/192 (6.8) 9/197 (4.6) 15/197 (7.6) 0.439
Death 2/192 (1.0) 1/197 (0.5) 2/197 (1.0) 0.874
MI 1/192 (0.5) 2/197 (1.0) 3/197 (1.5) 0.875
PCI* 7/192 (3.6) 5/197 (2.5) 9/197 (4.6) 0.555
PCI total 12/192 (6.3) 6/197 (3.0) 11/197 (5.6) 0.305
2-Year follow-up
MACE 22/192 (11.5%) 20/195 (10.3%) 27/195 (13.8%) 0.536
Death 5/192 (2.6%) 6/195 (3.1%) 7/195 (3.6%) 0.855
MI 4/192 (2.1%) 3/195 (1.5%) 4/195 (2.1%) 0.933
PCI* 10/192 (5.2%) 8/195 (4.1%) 13/195 (6.7%) 0.528
Values are n/N or n/N (%). Angiographic restenosis is deﬁned as restenosis >50% at 9-month
follow-up. Clinical procedural success is deﬁned as angiographic success (reduction in diameter
stenosis >50%, TIMI grade 3 ﬂow and no dissection higher than grade D1), without MACE. *PCI
of same segment.
MACE ¼ major adverse cardiac event(s); other abbreviations as in Table 1.
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755The secondary endpoint, clinical procedural success
without MACE, was encountered in 96.9% (DS), 97.5%
(CS), and 96.0% (PS) (p¼ 0.614). The exploratory endpoint
of angiographic restenosis at 9 months (stenosis 50%) was
signiﬁcantly more encountered within the PS group (DS,
3.4%; CS, 6.7%; PS, 11.5%; p ¼ 0.190 for comparison of
DS with CS and p ¼ 0.008 for comparison of DS with PS.
In the PS group, no stent was implanted in 23% of the
patients. In this group, restenosis occurred in 32% at 9-month
follow-up. In 77% of patients in whom a stent was implanted,
the rate of restenosis was 5%.
In the PS group, no stent was implanted in 23% of the
patients. In this group, restenosis occurred in 32% at 9-month
follow-up. In the 77% of patients in whom a stent was
implanted, the rate of restenosis was 5%.
Clinical outcome after 2-year follow-up. Clinical follow-up
was complete in 98.3% (9 months) and 97% (2 years) ofpatients. During the 2-year follow up, 18 patients died (3.1%),
11 patients experienced a myocardial infarction (1.9%), 45 pa-
tients underwent repeat PCI of the target lesion (7.7%), and 13
patients underwent CABG (2.2%). There were no signiﬁcant
differences among the 3 groups at either the 9-month or the
2-year follow-up (Table 2). Kaplan-Meier event-free survival
curves (Fig. 3) were similar (p ¼ 0.450; log-rank test).
Discussion
The main ﬁnding of the STRESSED study is that direct
DES implantation does not reduce restenosis compared with
conventional DES implantation.
Provisional DES implantation was associated with a higher
rate of restenosis compared with DS or CS; however, this
did not translate into a signiﬁcant difference in the rate of
MACE at 9-month and 20-year follow-up.
The provisional arm was included because the STRESSED
trial is a continuation of the DIRECT-2 study, comparing DS
with CS and PS in the BMS era. The study design was not
changed. It was still thought to be interesting to compare
differences between stenting groups and a provisional group,
although previous studies have shown balloon angioplasty to be
inferior to a stenting approach for restenosis (16). This most
likely explains the high rate of DES implantation in the PS
group. The acceptance of the result after balloon angioplasty
(stenting was allowed only if visual diameter stenosis after
repeated balloon dilation was >30%, if dissection was grade
Table 3. Angiographic Characteristics
Direct
Stenting
Conventional
Stenting
Provisional
Stenting p Value
MLD, mm
Pre-PCI 1.00  0.26 1.04  0.28 1.01  0.27 0.278*
0.708y
Post-PCI 2.35  0.41 2.45  0.40 2.34  0.48 0.044*
0.726y
9-month follow-up 2.12  0.58 2.17  0.67 1.99  0.69 0.556*
0.073y
Acute gainz 1.36  0.38 1.41  0.37 1.34  0.48 0.187
0.248*
0.460y
Late lossx 0.24  0.47 0.29  0.55 0.36  0.49 0.050
0.526*
0.017y
Reference diameter
pre-PCI, mm
2.56  0.48 2.66  0.50 2.63  0.47 0.190
0.083*
0.179y
Diameter stenosis, %
Pre-PCI 60.59  9.36 60.57  8.47 61.04  9.33 0.850
0.626*
0.617y
Post-PCI 8.29  10.62 7.84  10.06 12.08  13.37 0.009
0.783*
0.013y
9-month follow-up 17.33  18.08 18.74  19.59 24.71  21.49 0.005
0.679*
0.003y
Lesion length, mm
Pre-PCI 10.80  5.37 10.89  5.01 10.84  6.47 0.523
0.693*
0.452y
Post-PCI 14.79  7.31 14.95  6.14 14.17  8.21 0.079
0.215*
0.288y
9-month follow-up 15.21  6.72 15.09  5.73 14.80  6.96 0.517
0.392*
0.721y
Angiographic
restenosis
5/148 (3.4) 10/149 (6.7) 17/148 (11.5) 0.025
0.190*
0.008y
Balloon pre-dilation 35/196 (17.9) 199/201 (99.0) 197/200 (98.5) <0.001
<0.001*
<0.001y
Balloon size, maximal,
mm
2.77  0.53 3.22  5.12 2.94  0.39 0.002
0.124*
0.001y
Maximal pressure, atm 14.03  4.48 11.28  3.28 12.01  3.49 <0.001
<0.001*
0.001y
Balloon inﬂation after
stent implantation
46/196 (23.5) 46/201 (22.9) 26/200 (13.0) 0.013
0.890*
0.007y
Continued in the next column
Table 3. Continued
Direct
Stenting
Conventional
Stenting
Provisional
Stenting p Value
Total no. of stents 1.14  0.38 1.12  0.38 1.15  0.46 0.664
0.384*
0.879y
Maximal stent
diameter, mm
3.03  0.38 3.15  0.38 3.16  0.40 0.001
0.001*
0.002y
Total stent length, mm 19.75  8.59 20.51  7.84 21.83  10.84 0.017
0.043*
0.007y
Values shown are mean  SD or count/sample size (%). *For comparison of direct stenting with
conditional stenting. yFor comparison of direct stenting with provisional stenting. zAcute gain
is the MLD after stenting minus the MLD at baseline. xLate loss is the MLD after stenting minus
the MLD at follow-up.
MLD ¼ minimal lumen diameter; PCI ¼ percutaneous coronary intervention.
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756D1 or higher occurred, or if there was decreased TIMI ﬂow
after repeated dilation) was left to the discretion of the oper-
ator. It is likely that in case of any doubt, a DES would have
been implanted, leading to the high crossover rate.
The TAXUS ATLAS DIRECT STENT study (17)
showed similar amounts of neo-intimal hyperplasia after DSversus CS using DES, but DS was associated with reduced
rates of binary angiographic restenosis and ischemia-driven
target lesion revascularization. The patients in this trial,
however, were not randomized but propensity matched and
carefully selected for DS. The SIRIUS-DIRECT trial
(18) showed noninferiority for both safety and efﬁcacy in the
DS versus CS approach using the sirolimus-eluting Cypher
stent (Cordis, Bridgewater, New Jersey), and no differences
in target lesion revascularization and MACE. This study,
however, was nonrandomized, with signiﬁcant differences in
lesion characteristics between the 2 patient cohorts.
A recent meta-analysis by Piscione et al. (19) included 24
randomized trials comparing DS and CS strategies. Most of
the included trials were originally designed to evaluate a
possible role in reducing restenosis associated with DS
technique.
The main ﬁnding of this study was a signiﬁcantly lower
MACE rate in the DS group. This was mainly due to the
lower incidence of periprocedural myocardial infarction.
None of the included trials showed a signiﬁcant beneﬁt in
terms of target vessel revascularization or restenosis reduction.
The most likely mechanism of the release of troponin
after PCI is the occlusion of side branches or micro-
embolization of plaque debris (20); hence, the expected
theoretical advantage of DS is that distal microembolization
of plaque could be partly avoided, leading to a lower inci-
dence of myocardial infarction related to the procedure and
leading to a better TIMI ﬂow (21).
The exploratory biochemical endpoint of cTnT release in
our study showed a signiﬁcantly lower amount of myocardial
injury in the DS group. A meta-analysis by Feldman et al.
(22) indicates that cardiac troponin I or cTnT elevation after
nonemergent PCI is indicative of an increase in long-term
all-cause mortality and myocardial infarction.
The proposed mechanism of myocardial injury that im-
pairs left ventricular function promotes arrhythmias and
congestive heart failure, therefore resulting in decreased
long-term survival, is unlikely to play a role in patients with
Figure 2. Cumulative Frequency Distribution Curves
Minimal lumen diameters (MLD) (A) and percentage of diameter stenosis (B) as determined by quantitative coronary analysis before and after percutaneous coronary
intervention and at 9-month follow-up for the 3 groups.
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757minor cTnT elevations. Other possible mechanisms for the
decreased long-term survival in patients with cTnT elevation
are the extent of unstable coronary artery disease on pre-
sentation, leading to more complex coronary interventions
and the expectation that the amount of myocardial injury
post-PCI acts as a marker for the severity of atherosclerosis,
leading to a poorer long-term outcome. Considering these
mechanisms, it is unlikely that periprocedural efforts to
minimize small cTnT elevations after nonemergent PCI willFigure 3. Kaplan-Meier Curves
Showing freedom from major adverse cardiac events (MACE) up to 720 days after tresult in improved long-term outcomes. This is also shown
in recent publications by Pervaiz et al. (23) and Novack et al.
(24). In large studies, they showed that troponin elevations
after PCI of almost any amount have no prognostic rele-
vance, and, based on these studies, the prognostic implica-
tions of troponin release after PCI (especially the small
amounts noticed in the present study), are uncertain.
The myocardial infarction rate (deﬁned as an increase in
creatine kinase/creatine kinase-myocardial band more thanhe index procedure in each study group (p ¼ 0.450, log-rank test).
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758twice the upper limit of normal) that we encountered in our
study was 0.8%, without signiﬁcant differences among
groups. The rate of MI in the review article by Piscione et al.
(19) was 3.6%, with a signiﬁcant difference between DS
(3.16%) and CS (4.04%). This is most likely caused by the
different deﬁnitions of myocardial infarction that were used,
which makes it difﬁcult to compare different studies.
Study limitations. A limitation of our study was the higher-
than-expected loss of angiographic follow-up at 9 months. It
was assumed to be 25% (see sample size calculation in the
Statistical Analysis section). After completion of the trial,
this appeared to be somewhat higher (27%). Additionally,
patients who declined angiographic follow-up were older
and more often female. The acceptance rate after balloon
angioplasty in the PS group was quite low, with 77% stent
placement. Therefore, data were also analyzed with the per-
protocol approach, which showed results similar to the
intention-to-treat analysis. Furthermore, this study was not
powered to show differences in MACE, and the results
reﬂect the performance of a single institution.
Conclusions
Direct DES implantation compared with conventional
DES implantation does not reduce restenosis. Provisional
stenting, however, was associated with a higher rate of
restenosis. This did not translate into a difference in the rate
of MACE at short- and medium-term follow-up. Early and
medium-term MACE rates were comparably low in this
study, conﬁrming that a systematic DS strategy with second-
generation DES is associated with medium-term results as
favorable as those associated with a systematic strategy of
stenting after balloon pre-dilation.
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